Hong Kong regulators may be beefing up GMPs
This article was originally published in The Gold Sheet
Executive Summary
A review of Hong Kong's drug regulatory infrastructure could lead to more stringent GMP requirements for pharmaceutical manufactures, importers and distributors. A number of recent incidents have shaken public confidence in Hong Kong's regulatory system. The incidents ranged from drugs with fabricated expiration dates to tainted products distributed through government-run hospitals that have been linked to the deaths of six cancer patients. Under current regulations, manufacturers are responsible for registering locally made products. For imported products, the registration burden falls on the importer. Generic drugs that have been registered for more than five years do not have to produce clinical or scientific documentation on efficacy. Hong Kong regulators have enlisted the help of Australian drug experts to guide them in setting manufacturing standards for pharmaceuticals
You may also be interested in...
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Pipeline Watch: Five Approvals And 23 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.